GLP-1 Research Tracker

Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.

234 studies tracked·6 compounds covered·Updated Jul 2026

Has results

Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.

semaglutideliraglutide

CirculationFeb 2026

Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.

Diabetes, obesity & metabolismFeb 2026

Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis.

semaglutide

Online journal of public health informaticsFeb 2026

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

semaglutide

PeptidesFeb 2026

Combination of cardioprotective glucose-lowering drugs and statins on cardiovascular mortality in diabetes: a nationwide cohort study.

European journal of preventive cardiologyFeb 2026

Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.

International journal of dermatologyFeb 2026

Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery.

semaglutidetirzepatide

Heart (British Cardiac Society)Feb 2026

Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss.

tirzepatide

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy TechniciansFeb 2026

D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.

semaglutide

NutrientsFeb 2026

Mitochondrial Quality Control in Macrophages during Cardiovascular Disease.

The Canadian journal of cardiologyFeb 2026

Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient.

tirzepatide

Hospital pharmacyFeb 2026

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

semaglutide

Diabetes, obesity & metabolismFeb 2026

Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials.

tirzepatideliraglutide

Diabetes, obesity & metabolismFeb 2026

Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienneFeb 2026

Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study.

Diabetes, obesity & metabolismFeb 2026

Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

semaglutidetirzepatide

Journal of cardiovascular development and diseaseFeb 2026

Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment.

semaglutidetirzepatideliraglutide

Current obesity reportsFeb 2026

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.

semaglutidetirzepatideretatrutide

International journal of obesity (2005)Feb 2026

Secondary Prevention of Cardiovascular Events in Patients with Overweight/Obesity in Routine Clinical Practice.

semaglutide

medRxiv : the preprint server for health sciencesFeb 2026

Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.

orforglipron

Cardiovascular diabetology. Endocrinology reportsFeb 2026

Load more studies →

GLP-1 Research Tracker

Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.

Pre-Treatment Concerns and Their Association With Functioning and Well-Being During Incretin-Based Therapy: A Cross-Sectional Study.

Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis.

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Combination of cardioprotective glucose-lowering drugs and statins on cardiovascular mortality in diabetes: a nationwide cohort study.

Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Therapy for Hidradenitis Suppurativa in Patients With Overweight/Obesity: A Narrative Review of Efficacy, Safety, and Quality-of-Life Outcomes.

Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery.

Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss.

D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice.

Mitochondrial Quality Control in Macrophages during Cardiovascular Disease.

Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient.

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials.

Cost-effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists for patients with high cardiovascular risk and type 2 diabetes in Canada.

Comparative effectiveness of combination therapy with SGLT-2 inhibitors and GLP-1 RAs compared with SGLT-2 inhibitors in individuals with type 2 diabetes: A prevalent new-user cohort study.

Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment.

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.

Secondary Prevention of Cardiovascular Events in Patients with Overweight/Obesity in Routine Clinical Practice.

Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review.

Get Weekly Research Updates